How would Medicare coverage of anti-obesity drugs affect federal spending?
Core argument: Authorizing Medicare coverage of anti-obesity medications would raise net federal spending by about $35 billion over 2026–2034, with total direct federal costs rising from $1.6 billion in 2026 to $7.1 billion in 2034.
Authorizing coverage of anti-obesity medications (AOMs) in Medicare would increase federal spending, on net, by about $35 billion from 2026 to 2034. Total direct federal costs of covering AOMs would increase from $1.6 billion in 2026 to $7.1 billion in 2034. Relative to the direct costs of the medications, total savings from beneficiaries’ improved health would be small—less than $50 million in 2026 and rising to $1.0 billion in 2034. Weight loss is associated with reductions in health-related spending per user that are less than the estimated federal cost per user of covering AOMs throughout the 2026–2034 period. Per AOM user, the average direct federal cost would be roughly $5,600 in 2026, decreasing to $4,300 in 2034. And average offsetting federal savings would be about $50 in 2026, reaching $650 in 2034.


